Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 10:e32143.
doi: 10.1002/pbc.32143. Online ahead of print.

Real-World Use of Avatrombopag in Children and Adolescents With Immune Thrombocytopenia

Emily M Harris  1 , Caitlin Montcrieff  1 , Candelaria O'Farrell  2   3 , Praharsha Konde  4   5 , Michele P Lambert  4   5 , Amanda B Grimes  2 , Rachael F Grace  1
Affiliations

Real-World Use of Avatrombopag in Children and Adolescents With Immune Thrombocytopenia

Emily M Harris et al. Pediatr Blood Cancer. .

Abstract

Background: Avatrombopag, a second-generation thrombopoietin receptor agonist (TPO-RA), is approved for treatment of chronic immune thrombocytopenia (ITP) in adults and has been studied in a Phase 3 trial in pediatric ITP. The reported efficacy, oral administration, safety profile, and lack of dietary restrictions are appealing treatment characteristics for children. Data on real-world use in children are limited.

Methods: This multicenter cohort study included patients diagnosed with ITP at age < 21 years treated with avatrombopag. Clinical features were collected from electronic medical records. Overall platelet response was defined as platelet count ≥ 30 × 109/L and doubling from baseline.

Results: A total of 58 pediatric patients were treated with avatrombopag. Median time from diagnosis to treatment initiation was 4.6 years, with a median of 3 (range 0-11) prior treatments. Overall platelet response was 89.3% with similar response in primary and secondary ITP. Most patients achieved a response on the initial dose. Response rates did not differ by age at treatment initiation. Median time to platelet response was 13.5 days. High-grade bleeding scores were lower after initiation of treatment. Most patients (62%) switched from another TPO-RA to avatrombopag. Response to prior TPO-RA was associated with higher likelihood of response to avatrombopag (OR 15.00, 95% CI 1.824-187.7, p = 0.017). Of 12 patients with no response to prior TPO-RA, 8 responded to avatrombopag. Adverse effects were rare.

Conclusions: In this real-world study, avatrombopag was highly effective at both improving platelet counts and reducing bleeding in children with ITP, even in patients with secondary ITP or who had failed other TPO-RAs.

Keywords: avatrombopag; immune thrombocytopenia; pediatric; thrombopoietin receptor agonist; treatment.

PubMed Disclaimer

References

    1. C. Neunert, D. R. Terrell, D. M. Arnold, et al., “American Society of Hematology 2019 Guidelines for Immune Thrombocytopenia,” Blood Advances 3 (2019): 3829–3866.
    1. W. Jurczak, K. Chojnowski, J. Mayer, et al., “Phase 3 Randomised Study of Avatrombopag, a Novel Thrombopoietin Receptor Agonist for the Treatment of Chronic Immune Thrombocytopenia,” British Journal of Haematology 183 (2018): 479–490.
    1. “Package Insert,” Doptelet, 2025, https://doptelet.com/themes/pdf/prescribing‐information.pdf.
    1. C. Labanca, E. Vigna, E. A. Martino, et al., “Avatrombopag for the Treatment of Immune Thrombocytopenia,” European Journal of Haematology 114 (2025): 733–746.
    1. A. Oladapo, S. Kolodny, M. Vredenburg, et al., “Avatrombopag Treatment Response in Patients With Immune Thrombocytopenia: The REAL‐AVA 1.0 Study,” Therapeutic Advances in Hematology 14 (2023): 20406207231179856.

LinkOut - more resources